

Embargo: November 13, 2008 at 5:40 PM (Brussels Time)

SOLVAY GROUP HOLDS 95.33% OF INNOGENETICS SHARES

Solvay will proceed with squeeze-out of remaining Innogenetics shares and request delisting

Solvay Pharmaceuticals S.A., a subsidiary of the Solvay Group, the chemical and pharmaceutical group, today announced that it will acquire 690,289 additional shares of Innogenetics nv, a Belgian-based biotechnological company, in a cash transaction valued at EUR 6.5 per share, representing EUR 200.7 million for 100% of the Innogenetics shares. The shares were offered to Solvay Pharmaceuticals during the third offer period for Innogenetics, which ran from 22 October to 12 November 2008.

After closing of the offer, which is expected on 20 November, Solvay Group will hold 95.33% of the Innogenetics shares, the participation of 9.68% which Solvay Group held prior to the offer included. In accordance with Belgian law, Solvay will proceed with a squeeze-out of the remaining Innogenetics shares, which will run from 21 November to 11 December 2008. Solvay will also request NYSE Euronext Brussels to delist the Innogenetics shares which delisting is expected to become effective on 12 December 2008.

“We are extremely pleased with the positive response of the Innogenetics shareholders. After closing of the squeeze-out, we can fully focus on further implementing our dual strategy: expansion of Innogenetics’ diagnostics business and leverage of both companies’ R&D competencies to accelerate the development of Solvay’s therapeutic pipeline through the implementation of biomarker, diagnostics and eventually companion diagnostics technologies”, said Werner Cautreels, CEO of Solvay Pharmaceuticals.

SOLVAY PHARMACEUTICALS S.A. is a Belgian fully-owned subsidiary of Solvay Group.

SOLVAY PHARMACEUTICALS is a research driven group of companies that constitutes the global pharmaceutical business of the Solvay Group. These companies seek to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardiometabolic, influenza vaccines, gastroenterology and men's and women's health. Its 2007 sales were EUR 2.6 billion, and it employs more than 9,000 people worldwide. For more information, visit www.solvaypharmaceuticals.com.

SOLVAY GROUP is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs more than 28,000 people in 50 countries. In 2007, its consolidated sales amounted to EUR 9.6 billion, generated by its three sectors of activity: Chemicals, Plastics and Pharmaceuticals. Solvay is listed on the NYSE Euronext stock exchange in Brussels (NYSE Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR). Details are available at www.solvay.com.

For further information please contact:

ERIK DE LEYE
Corporate Press Officer
SOLVAY S.A.
Tel: +32 2 509 7230
erik.deleye@solvay.com
www.solvaypress.com

Dr WERNER VAN DEN EYNDE, MD
Pharmaceutical Communications
SOLVAY PHARMACEUTICALS S.A.
Tel: +32 2 509 6227
werner.vandeneynde@solvay.com
www.solvaypharmaceuticals.com

PATRICK VERELST
Investor Relations
SOLVAY S.A.
Tel. +32 2 509 7243
patrick.verelst@solvay.com
www.solvay-investors.com

Ce communiqué de presse est également disponible en français – Dit persbericht is ook in het Nederlands beschikbaar

The Prospectus (including the Acceptance Form and the Supplements) is available on the website of Solvay on www.solvay.com.